Full-Time
Imaging Informatics Marketing Manager
Cloud Services
Philips
Healthcare technology for diagnosis, care, wellness
Compensation Overview
$135.2k - $216.4k/yr
No H1B Sponsorship
Cambridge, MA, USA
In Person
Must reside in or within commuting distance to Cambridge, MA.
 Growth & Marketing (1) |
|---|
- 5+ years of experience in Radiology/Cardiology Informatics, with proven customer-facing expertise
- Skills include product and solution launch management, market insights, value proposition development, pricing strategies, SaaS/cloud business knowledge, and go-to-market strategy execution
- Bachelor’s degree in marketing, life sciences, healthcare, or a related field
- US work authorization is a precondition of employment
- You must reside in or within commuting distance to Cambridge, MA.
- Lead go-to-market activities for new imaging informatics cloud services, including launch plans, sales enablement, collateral development, and pricing strategies specifically across cardiovascular and radiology domains
- Partner with cross-functional teams—Senior Product Managers, Go-To-Market, clinical marketing, and global business units—to translate the radiology roadmap into customer-centric value propositions
- Develop commercial solutions and integrated marketing campaigns by leveraging market research, competitive intelligence, and customer insights to inform strategy
- Advocate for customer-centricity and solution-focused approaches, applying design thinking and breaking down silos across business units
- Collaborate globally with multinational teams to ensure compliance, alignment, and impactful execution of marketing initiatives
Philips develops health technology across professional medical devices, connected care, and consumer health products. Its offerings include diagnostic imaging and image-guided therapy, patient monitoring and clinical informatics, and everyday wellness products like oral and personal care. The company increasingly delivers integrated solutions through a Healthcare-as-a-Service subscription model and long-term partnerships with hospitals and health systems. Its aim is to improve people’s health and well-being by making advanced health technology easier to access and integrate into care.
Company Size
N/A
Company Stage
IPO
Headquarters
Andover, Minnesota
Founded
1891
Simplify's Take
What believers are saying
- Aims to improve 2.5 billion lives yearly by 2030 via partnerships.
- Partnered with HealthAlliance Hospital for advanced imaging and monitoring.
- Strong global presence in North America, Europe, and emerging markets.
What critics are saying
- 2021 Respironics recall triggers ongoing lawsuits and erodes Connected Care trust.
- GE HealthCare's AI MRI scanners outperform Philips in speed and quality.
- $1.1 billion DreamStation settlement drains cash and deters HaaS deals.
What makes Philips unique
- Philips segments into Diagnosis & Treatment, Connected Care, and Personal Health.
- Shifting to Healthcare-as-a-Service model with subscription-based solutions.
- Launched Shavetopia metaverse in Roblox for Movember men's health awareness.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Health Savings Account/Flexible Spending Account
Company News
<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US, subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024. The company’s previously announced 2023-2025 financial outlook remains unchanged, already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more
Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.
In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.
February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.
Register now for your free virtual pass to the Low-Code/No-Code Summit this November 9. Hear from executives from Service Now, Credit Karma, Stitch Fix, Appian, and more. Learn more. Philips Norelco is creating an interactive metaverse experience called Shavetopia in Roblox, based around the Movember trend. For anyone who doesn’t know what that is, Movember is where people grow facial hair for the entire month of November. The portmanteau comes from adding the word mustache to the name of the month